Foundation rises on NSCLC deals

Foundation Medicine Inc. (NASDAQ:FMI) gained $1.47 to $22.37 on Monday after it said UnitedHealth Group inc. (NYSE:UNH) agreed to cover its FoundationOne genomic profiling assay for patients with metastatic stage IV non-small cell lung cancer. FoundationOne is a laboratory-developed test (LDT) that identifies all somatically altered genes that are validated targets for therapy or drivers of oncogenesis. ...